Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gel injection aims to smooth out acne scars

NCT ID NCT05995340

Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 18, 2026 · Updated 2 times

Summary

This study tests an injectable gel called ELAPR002f for adults with indented acne scars on the cheeks. About 157 participants will receive either the gel or a saline placebo over 2 months and be followed for a year. The goal is to see if the gel safely fills in scars and improves appearance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

157 people

The number who actually took part.

Started

Nov 2023

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants in general good health, with no active COVID-19 infection, and seeking improvement of atrophic acne scars. * Moderate to severe atrophic acne scarring (Grade 4 or 5 on the Allergan ASIS) on each cheek based on Evaluating Investigator's live assessment (both cheeks must qualify but do not need to have the same score) at the first screening visit. * At least 5 rolling or boxcar-type acne scars in total within the predefined assessment field of either cheek in areas of otherwise normal healthy skin, as assessed by the treating investigator. Exclusion Criteria: * The participant has clinically significant acne on the face. * Current cutaneous or mucosal inflammatory or infectious processes other than acne (eg, herpes), rosacea, abscess, an unhealed wound, or a cancerous or precancerous lesion, on the face. * The participant presents with predominantly ice pick scars. * History of keloid scar formation, hypertrophic scarring and/or post inflammatory hyperpigmentation or hypopigmentation. * History of granulomatous or connective tissue disease. * Diagnosed autoimmune disease (eg, Type 1 diabetes, rheumatoid arthritis, scleroderma, vitiligo). * Diagnosed history of lung disease. * Known hypersensitivity to the constituents of the device. * Visual acuity of 20/100 or worse or abnormal confrontational visual fields or ocular motility.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrophic acne scars are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrophic acne scars

Contacts and locations

Locations

  • Alberta DermaSurgery Centre /ID# 243168

    Edmonton, Alberta, T6G 1C3, Canada

  • Bertucci MedSpa Inc. /ID# 227468

    Woodbridge, Ontario, L4L 8E2, Canada

  • Dermatologie Mahlow /ID# 262566

    Blankenfelde-Mahlow, Brandenburg, 15831, Germany

  • Dermetics Cosmetic Dermatology /ID# 227469

    Burlington, Ontario, L7N 3N2, Canada

  • Hautok and Hautok-cosmetics /ID# 227474

    Munich, Bavaria, 80333, Germany

  • Humphrey & Beleznay Cosmetic Dermatology /ID# 266634

    Vancouver, British Columbia, V5Z 4E1, Canada

  • MVZ Corius MediCorium GmbH /ID# 227475

    Friedrichsdorf, Hesse, 61381, Germany

  • Pacific Derm /ID# 227467

    Vancouver, British Columbia, V6H 4E1, Canada

  • Privatpraxis Dr. Hilton & Partner /ID# 227472

    Düsseldorf, North Rhine-Westphalia, 40212, Germany

  • Rosenpark Research /ID# 227471

    Darmstadt, Hesse, 64283, Germany

  • The Center For Dermatology /ID# 227470

    Richmond Hill, Ontario, L4B 1A5, Canada

  • The Centre For Clinical Trials /ID# 233841

    Oakville, Ontario, L6J 7W5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.